Amylyx Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Amylyx Pharmaceuticals generated cash of $11,919,000, which is more than the previous year. Cash used in financing activities reached the amount of $3,543,000 last year. Net change in cash is therefore $107,675,000.
Cash Flow
| 2019 | -10.68M | 0 | 668K |
|---|---|---|---|
| 2020 | -36.69M | -151K | 46.82M |
| 2021 | -74.79M | -46.40M | 158.50M |
| 2022 | -179.87M | -238.98M | 431.78M |
| 2023 | 11.91M | 92.05M | 3.54M |
AMLX Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 63.24M | 50.38M | 13.06M | 3.09M | 13.11M |
Operating activities | |||||
Net income | 49.27M | -198.37M | -87.93M | -42.28M | -13.71M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 1.08M | 487K | 52K | 1K | 0 |
Stock-based compensation expense | 37.16M | 21.71M | 3.13M | 243K | 108K |
| Deferred income tax benefit | 37.16M | 21.71M | 3.13M | 243K | 108K |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | -15.30M | 0 | 0 | 0 |
Inventories | 0 | -9.76M | 0 | 0 | 0 |
Accounts payable | 15.88M | 1.85M | 670K | 1.41M | 1.28M |
Cash generated by operating activities | 11.91M | -179.87M | -74.79M | -36.69M | -10.68M |
Investing activities | |||||
Purchases Of Investments | -300.82M | -415.87M | -49.05M | 0 | 0 |
Investments In Property Plant And Equipment | -1.24M | -2.52M | -353K | -151K | 0 |
Acquisitions Net | 0 | 236.46M | -3M | 0 | 0 |
Cash generated by investing activities | 92.05M | -238.98M | -46.40M | -151K | 0 |
Financing activities | |||||
Common Stock Issued | 6.85M | 432.44M | 135M | 30.00M | 27K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -3.31M | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -263K | -16.81M | 641K |
Cash used in financing activities | 3.54M | 431.78M | 158.50M | 46.82M | 668K |
Net Change In Cash | 107.67M | 12.86M | 37.31M | 9.97M | -10.01M |
Cash at end of period | 170.92M | 63.24M | 50.38M | 13.06M | 3.09M |
| Data source | Data source | Data source |